|
"ducreux m"的相關文件
顯示項目 1-7 / 7 (共1頁)
1
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2024-08-06 |
Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer
|
Chen, LT;Vogel, A;Hsu, C;Chen, MH;Fang, W;Pangarsa, EA;Sharma, A;Ikeda, M;Park, JO;Tan, CK;Regala, E;Tai, D;Tanasanvimon, S;Charoentum, C;Chee, CE;Lui, A;Sow, J;Oh, DY;Ueno, M;Ramaswamy, A;Jeo, WS;Zhou, J;Curigliano, G;Yoshino, T;Bai, LY;Pentheroudakis, G;Chiang, NJ;Cervantes, A;Chen, JS;Ducreux, M |
| 國立成功大學 |
2023 |
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial
|
Ren, Z.;Ducreux, M.;Abou-Alfa, G.K.;Merle, P.;Fang, W.;Edeline, J.;Li, Z.;Wu, L.;Assenat, E.;Hu, S.;Rimassa, L.;Zhang, T.;Blanc, J.-F.;Pan, H.;Ross, P.;Yen, C.-J.;Tran, A.;Shao, G.;Bouattour, M.;Chen, Y.;Meyer, T.;Hou, J.;Tougeron, D.;Bai, Y.;Hou, M.-M.;Meng, Z.;Wu, J.;Li, V.;Chica-Duque, S.;Cheng, A.-L. |
| 臺大學術典藏 |
2022-02-21T02:04:34Z |
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
|
Galle P.R.; Finn R.S.; Qin S.; Ikeda M.; Zhu A.X.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.; Li D.; Mulla S.; Verret W.; Xu D.-Z.; Hernandez S.; Ding B.; Liu J.; Huang C.; Lim H.Y.; ANN-LII CHENG; Ducreux M. |
| 臺大學術典藏 |
2021-08-31T06:29:17Z |
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
|
Finn R.S.; Qin S.; Ikeda M.; Galle P.R.; Ducreux M.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.O.; Li D.; Verret W.; Xu D.-Z.; Hernandez S.; Liu J.; Huang C.; Mulla S.; Wang Y.; Lim H.Y.; Zhu A.X.; ANN-LII CHENG; IMbrave150 Investigators |
| 臺大學術典藏 |
2021-01-28T01:06:14Z |
Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan
|
Kun-Huei Yeh;Yang T.-S.;Hsu T.-C.;Tzu-Liang Chen W.;Chen H.-H.;Teng H.-W.;Lin B.-W.;Kuan F.-C.;Chiang F.-F.;Duann C.-W.;Li Y.-S.;Lin M.-T.;Fiala-Buskies S.;Ducreux M.;Wang J.-Y.; KUN-HUEI YEH; Yang T.-S.; Hsu T.-C.; Tzu-Liang Chen W.; Chen H.-H.; Teng H.-W.; Lin B.-W.; Kuan F.-C.; Chiang F.-F.; Duann C.-W.; Li Y.-S.; Lin M.-T.; Fiala-Buskies S.; Ducreux M.; Wang J.-Y. |
| 臺大學術典藏 |
2021-01-28T01:06:14Z |
Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan
|
Kun-Huei Yeh;Yang T.-S.;Hsu T.-C.;Tzu-Liang Chen W.;Chen H.-H.;Teng H.-W.;Lin B.-W.;Kuan F.-C.;Chiang F.-F.;Duann C.-W.;Li Y.-S.;Lin M.-T.;Fiala-Buskies S.;Ducreux M.;Wang J.-Y.; KUN-HUEI YEH; Yang T.-S.; Hsu T.-C.; Tzu-Liang Chen W.; Chen H.-H.; Teng H.-W.; Lin B.-W.; Kuan F.-C.; Chiang F.-F.; Duann C.-W.; Li Y.-S.; Lin M.-T.; Fiala-Buskies S.; Ducreux M.; Wang J.-Y. |
| 國立成功大學 |
2021 |
Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan
|
Yeh, K.-H.;Yang, T.-S.;Hsu, T.-C.;Tzu-Liang, Chen W.;Chen, H.-H.;Teng, H.-W.;Lin, B.-W.;Kuan, F.-C.;Chiang, F.-F.;Duann, C.-W.;Li, Y.-S.;Lin, M.-T.;Fiala-Buskies, S.;Ducreux, M.;Wang, J.-Y. |
顯示項目 1-7 / 7 (共1頁)
1
每頁顯示[10|25|50]項目
|
